Presentation is loading. Please wait.

Presentation is loading. Please wait.

Menstrual symptoms by intrauterine device type.

Published byMaud Wiggins Modified over 5 years ago

Similar presentations

Presentation on theme: "Menstrual symptoms by intrauterine device type."— Presentation transcript:

1 Menstrual symptoms by intrauterine device type.
Menstrual symptoms by intrauterine device type. Percentage of women reporting symptoms at 6 months of 64 levonorgestrel intrauterine system (LNG-IUS) users and 19 Cu T 380A intrauterine device users. *p<0.05 for difference between LNG-IUS and Cu T 380A. Alexandra M Hall, and Beth A Kutler J Fam Plann Reprod Health Care doi: /jfprhc Copyright © by the BMJ Publishing Group Ltd & the Faculty of Sexual & Reproductive Healthcare of the Royal College of Obstetricians & Gynaecologists. All rights reserved.

Download ppt "Menstrual symptoms by intrauterine device type."

Similar presentations

ADHD and comorbidity in Swedish school age children

ADHD and comorbidity in Swedish school age children
 Categorisation of direct and indirect admissions to the intensive care unit (ICU) from emergency departments (EDs), using source of admission.  Categorisation.

 Categorisation of direct and indirect admissions to the intensive care unit (ICU) from emergency departments (EDs), using source of admission.  Categorisation.
Number of days from insertion of intrauterine device or intrauterine system to first major event in patients receiving frequent or infrequent systematic.

Number of days from insertion of intrauterine device or intrauterine system to first major event in patients receiving frequent or infrequent systematic.
 Correlation between plasma total antioxidant capacity of plasma (TAC) and protein SH groups (SH) (A), total hydroperoxide concentration (TH) and TAC (B),

 Correlation between plasma total antioxidant capacity of plasma (TAC) and protein SH groups (SH) (A), total hydroperoxide concentration (TH) and TAC (B),
(A) Headbox oxygen; (B) facemask; (C) oxygen administration by holding an oxygen source near the infant’s face; (D) nasal cannulae; (E) nasal catheter;

(A) Headbox oxygen; (B) facemask; (C) oxygen administration by holding an oxygen source near the infant’s face; (D) nasal cannulae; (E) nasal catheter;
ECG showing appearances of polymorphic ventricular complexes on exercise testing in a patient who is β-blocked and known to have catecholaminergic polymorphic.

ECG showing appearances of polymorphic ventricular complexes on exercise testing in a patient who is β-blocked and known to have catecholaminergic polymorphic.
Box plot of subarachnoid space measurements at each gestational week of age. Box plot of subarachnoid space measurements at each gestational week of age.

Box plot of subarachnoid space measurements at each gestational week of age. Box plot of subarachnoid space measurements at each gestational week of age.
Box plot of head circumference measurements at each gestational week of age. Box plot of head circumference measurements at each gestational week of age.

Box plot of head circumference measurements at each gestational week of age. Box plot of head circumference measurements at each gestational week of age.
Pulse field gel electrophoresis: Lane 1 Lamda marker; lanes 2 to 5 K pneumoniae isolates from cases 3 to 6; lane 6 isolate from case 7; lane 7 ESBL negative.

Pulse field gel electrophoresis: Lane 1 Lamda marker; lanes 2 to 5 K pneumoniae isolates from cases 3 to 6; lane 6 isolate from case 7; lane 7 ESBL negative.
 (A) Diffusion weighted magnetic resonance imaging (MRI) scan of the brain of a full term male infant 56 hours after birth, showing parasagittal changes.

 (A) Diffusion weighted magnetic resonance imaging (MRI) scan of the brain of a full term male infant 56 hours after birth, showing parasagittal changes.
(A) Increasing shunt (from 0 to 40%) lowers the curve.

(A) Increasing shunt (from 0 to 40%) lowers the curve.
Example of data analysis from infant I

Example of data analysis from infant I
Flow chart of patients undergoing intra-caesarean insertion of postplacental intrauterine contraceptive device (PPIUD). Flow chart of patients undergoing.

Flow chart of patients undergoing intra-caesarean insertion of postplacental intrauterine contraceptive device (PPIUD). Flow chart of patients undergoing.
Plot of average differences in arterial blood pressure using the two methods in mm Hg against both methods for systolic blood pressure (A) and diastolic.

Plot of average differences in arterial blood pressure using the two methods in mm Hg against both methods for systolic blood pressure (A) and diastolic.
 Schematic representation of the two types of gastric volvulus: organoaxial volvulus occurs around the line A–A and mesenteroaxial volvulus occurs around.

 Schematic representation of the two types of gastric volvulus: organoaxial volvulus occurs around the line A–A and mesenteroaxial volvulus occurs around.
Diagrammatic representation of a peripheral villous tree, showing a large central stem villus: the lateral branches from this are the mature intermediate.

Diagrammatic representation of a peripheral villous tree, showing a large central stem villus: the lateral branches from this are the mature intermediate.
Examples of Mirena® Haptic ‘end effectors’

Examples of Mirena® Haptic ‘end effectors’
Box plot representation of serum cytokines levels (pg/ml) in group A (nasal continuous positive airway pressure (NCPAP)) and group B (bi-level NCPAP) at.

Box plot representation of serum cytokines levels (pg/ml) in group A (nasal continuous positive airway pressure (NCPAP)) and group B (bi-level NCPAP) at.
Barriers and Misperceptions Limiting Widespread Use of Intrauterine Contraception Among Canadian Women  Brian Hauck, MD, FRCSC, Dustin Costescu, MD, BSc,

Barriers and Misperceptions Limiting Widespread Use of Intrauterine Contraception Among Canadian Women  Brian Hauck, MD, FRCSC, Dustin Costescu, MD, BSc,
Proportion of overall use stratified by age over the study period for (A) cyproterone acetate/ethinylestradiol, (B) levonorgestrel/ethinylestradiol and.

Proportion of overall use stratified by age over the study period for (A) cyproterone acetate/ethinylestradiol, (B) levonorgestrel/ethinylestradiol and.

Similar presentations

Ads by Google